Brind.
  1. Scott Galloway critiques SpaceX's IPO valuation and recommends Eli Lilly, noting both companies are involved in the GLP-1 drug market.

Cathie Wood views SpaceX as a deep value play while Scott Galloway maintains opposing valuation views.

3 reports, 1 independent Updated Sep 16
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Cathie Wood views SpaceX as a deep value play while Scott Galloway maintains opposing valuation views.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story